Lineage Cell Therapeutics
LCTX
LCTX
101 hedge funds and large institutions have $103M invested in Lineage Cell Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 28 closing their positions.
Holders
101
Holders Change
-9
Holders Change %
-8.18%
% of All Funds
1.71%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
20
Increased
18
Reduced
24
Closed
28
Calls
$268K
Puts
$17K
Net Calls
+$251K
Net Calls Change
-$21K
Top Buyers
| 1 |
LCM
1
Laurion Capital Management
New York
|
$3.83M |
| 2 |
2
Millennium Management
New York
|
$1.61M |
| 3 |
RA
3
Raffles Associates
New York
|
$3.05M |
| 4 |
E
4
Ergoteles
New York
|
$875K |
| 5 |
BCM
5
Bridgeway Capital Management
Houston,
Texas
|
$623K |
Top Sellers
| 1 |
1
BlackRock
New York
|
$5.93M |
| 2 |
2
State Street
Boston,
Massachusetts
|
$695K |
| 3 |
3
Geode Capital Management
Boston,
Massachusetts
|
$1.97M |
| 4 |
4
Northern Trust
Chicago,
Illinois
|
$319K |
| 5 |
5
JPMorgan Chase & Co
New York
|
$1.99M |
